Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

AUTOR(ES)

Rabaglio, M.

FONTE

Oxford University Press

RESUMO

Background: To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial.

Documentos Relacionados

• Exemestane is better than tamoxifen in years 2-5 after breast cancer
• Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.
• Women treated for early breast cancer should be followed for at least 10 years
• Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases.
• The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up